The impact of COVID-19 on familial Mediterranean fever: a nationwide study
Abstract The study aimed to evaluate the impact of the coronavirus disease 2019 (COVID-19) in patients with familial Mediterranean fever (FMF) and to assess the relationships between FMF characteristics and severe COVID-19 outcomes such as hospitalization. The study was planned within a national network of 21 different centers. Demographics, FMF-related clinical and genetic characteristics, and COVID-19 outcomes were obtained. A total of 822 patients with FMF (mean age of 36 years) were included in the study. Fifty-nine of them (7%) had a COVID-19 diagnosis confirmed by real-time PCR test or chest CT findings. Most FMF patients with COVID-19 (58) had mild and moderate disease activity. All patients were on colchicine treatment. However, 8 of them (13.6%) were not compliant with colchicine use and 9 of them (15.3%) were colchicine resistant. Twelve FMF patients with COVID-19 were hospitalized. There were 4 patients requiring oxygen support. COVID-19 related complications were observed in 2 patients (1 thromboembolism, 1 acute respiratory distress syndrome). Hospitalized COVID-19 patients with FMF were older than non-hospitalized patients (median ages: 51 and 31 years, respectively; p: 0.002). Other FMF-related characteristics were similar between the groups. FMF-related characteristics were not found to be associated with poor outcomes in COVID-19. Thus, FMF may not be a risk factor for poor COVID-19 outcomes..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
---|---|
Enthalten in: |
Rheumatology international - 41(2021), 8 vom: 25. Mai, Seite 1447-1455 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Günendi, Zafer [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
BKL: | |
---|---|
Themen: |
COVID-19 |
Anmerkungen: |
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 |
---|
doi: |
10.1007/s00296-021-04892-6 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR04444267X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR04444267X | ||
003 | DE-627 | ||
005 | 20230519194607.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210701s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s00296-021-04892-6 |2 doi | |
035 | |a (DE-627)SPR04444267X | ||
035 | |a (SPR)s00296-021-04892-6-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q ASE |
082 | 0 | 4 | |a 610 |q ASE |
084 | |a 44.83 |2 bkl | ||
100 | 1 | |a Günendi, Zafer |e verfasserin |4 aut | |
245 | 1 | 4 | |a The impact of COVID-19 on familial Mediterranean fever: a nationwide study |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 | ||
520 | |a Abstract The study aimed to evaluate the impact of the coronavirus disease 2019 (COVID-19) in patients with familial Mediterranean fever (FMF) and to assess the relationships between FMF characteristics and severe COVID-19 outcomes such as hospitalization. The study was planned within a national network of 21 different centers. Demographics, FMF-related clinical and genetic characteristics, and COVID-19 outcomes were obtained. A total of 822 patients with FMF (mean age of 36 years) were included in the study. Fifty-nine of them (7%) had a COVID-19 diagnosis confirmed by real-time PCR test or chest CT findings. Most FMF patients with COVID-19 (58) had mild and moderate disease activity. All patients were on colchicine treatment. However, 8 of them (13.6%) were not compliant with colchicine use and 9 of them (15.3%) were colchicine resistant. Twelve FMF patients with COVID-19 were hospitalized. There were 4 patients requiring oxygen support. COVID-19 related complications were observed in 2 patients (1 thromboembolism, 1 acute respiratory distress syndrome). Hospitalized COVID-19 patients with FMF were older than non-hospitalized patients (median ages: 51 and 31 years, respectively; p: 0.002). Other FMF-related characteristics were similar between the groups. FMF-related characteristics were not found to be associated with poor outcomes in COVID-19. Thus, FMF may not be a risk factor for poor COVID-19 outcomes. | ||
650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
650 | 4 | |a Familial Mediterranean fever |7 (dpeaa)DE-He213 | |
650 | 4 | |a Rheumatic diseases |7 (dpeaa)DE-He213 | |
650 | 4 | |a Colchicine |7 (dpeaa)DE-He213 | |
650 | 4 | |a Hospitalization |7 (dpeaa)DE-He213 | |
650 | 4 | |a Poor outcomes |7 (dpeaa)DE-He213 | |
700 | 1 | |a Yurdakul, Fatma Gül |e verfasserin |4 aut | |
700 | 1 | |a Bodur, Hatice |e verfasserin |4 aut | |
700 | 1 | |a Cengiz, Ahmet Kıvanç |e verfasserin |4 aut | |
700 | 1 | |a Uçar, Ülkü |e verfasserin |4 aut | |
700 | 1 | |a Çay, Hasan Fatih |e verfasserin |4 aut | |
700 | 1 | |a Şen, Nesrin |e verfasserin |4 aut | |
700 | 1 | |a Keskin, Yaşar |e verfasserin |4 aut | |
700 | 1 | |a Gürer, Gülcan |e verfasserin |4 aut | |
700 | 1 | |a Melikoğlu, Meltem Alkan |e verfasserin |4 aut | |
700 | 1 | |a Altıntaş, Duygu |e verfasserin |4 aut | |
700 | 1 | |a Deveci, Hülya |e verfasserin |4 aut | |
700 | 1 | |a Baykul, Merve |e verfasserin |4 aut | |
700 | 1 | |a Nas, Kemal |e verfasserin |4 aut | |
700 | 1 | |a Çevik, Remzi |e verfasserin |4 aut | |
700 | 1 | |a Karahan, Ali Yavuz |e verfasserin |4 aut | |
700 | 1 | |a Toprak, Murat |e verfasserin |4 aut | |
700 | 1 | |a Ketenci, Sertaç |e verfasserin |4 aut | |
700 | 1 | |a Nayimoğlu, Mehmet |e verfasserin |4 aut | |
700 | 1 | |a Sezer, İlhan |e verfasserin |4 aut | |
700 | 1 | |a Demir, Ali Nail |e verfasserin |4 aut | |
700 | 1 | |a Ecesoy, Hilal |e verfasserin |4 aut | |
700 | 1 | |a Duruöz, Mehmet Tuncay |e verfasserin |4 aut | |
700 | 1 | |a Yurdakul, Ozan Volkan |e verfasserin |4 aut | |
700 | 1 | |a Sarıfakıoğlu, Ayşe Banu |e verfasserin |4 aut | |
700 | 1 | |a Ataman, Şebnem |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Rheumatology international |d Berlin : Springer, 1981 |g 41(2021), 8 vom: 25. Mai, Seite 1447-1455 |w (DE-627)SPR00382473X |w (DE-600)1464208-6 |x 1437-160X |7 nnns |
773 | 1 | 8 | |g volume:41 |g year:2021 |g number:8 |g day:25 |g month:05 |g pages:1447-1455 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00296-021-04892-6 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
936 | b | k | |a 44.83 |q ASE |
951 | |a AR | ||
952 | |d 41 |j 2021 |e 8 |b 25 |c 05 |h 1447-1455 |